Date: November 21, 2026

Regulatory Compliance Update

Aurobindo Pharma Limited disclosed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the United States Food and Drug Administration (USFDA) inspection of Unit-VI, an API manufacturing facility of its wholly owned subsidiary Apitoria Pharma Private Limited, has been closed.

Inspection Details

  • Facility: Unit-VI, API manufacturing facility of Apitoria Pharma Private Limited
  • Location: E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh
  • Inspection Period: August 24 to August 28, 2026
  • Observations: Concluded with three observations

Inspection Outcome

  • Classification: Voluntary Action Indicated (VAI)
  • Status: Inspection is now closed
  • Documentation: Establishment Inspection Report (EIR) received

Reference

This disclosure references the company's previous letter dated August 28, 2026.